Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

196 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Allopurinol as a cardiovascular drug.
Kelkar A, Kuo A, Frishman WH. Kelkar A, et al. Cardiol Rev. 2011 Nov-Dec;19(6):265-71. doi: 10.1097/CRD.0b013e318229a908. Cardiol Rev. 2011. PMID: 21983313 Review.
Although traditionally the cornerstone therapy for gout, allopurinol's ability to be a competitive inhibitor of the key enzyme, xanthine oxidase, needed for uric acid formation, has prompted recent clinical research evaluating allopurinol as a CV drug. ...This revie …
Although traditionally the cornerstone therapy for gout, allopurinol's ability to be a competitive inhibitor of the key enzyme, xanth …
Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells.
Kelkar AA, Butler J, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun W, Luger D, Epstein SE. Kelkar AA, et al. J Am Coll Cardiol. 2015 Nov 3;66(18):2038-2047. doi: 10.1016/j.jacc.2015.09.010. J Am Coll Cardiol. 2015. PMID: 26516007 Review.
A reassessment of the rationale for the use of stem cells in cardiovascular disease is therefore timely. Such a rationale should include analyses of why previous trials have not produced significant benefit and address whether mechanisms contributing to disease prog
A reassessment of the rationale for the use of stem cells in cardiovascular disease is therefore timely. Such a rationale shou
Trends in Consent for Clinical Trials in Cardiovascular Disease.
Kerkhoff LA, Butler J, Kelkar AA, Shore S, Speight CD, Wall LK, Dickert NW. Kerkhoff LA, et al. Among authors: kelkar aa. J Am Heart Assoc. 2016 Jun 17;5(6):e003582. doi: 10.1161/JAHA.116.003582. J Am Heart Assoc. 2016. PMID: 27317350 Free PMC article. Review.
Prognostic significance of blood pressure response during vasodilator stress Rb-82 positron emission tomography myocardial perfusion imaging.
Witbrodt B, Goyal A, Kelkar AA, Dorbala S, Chow BJW, Di Carli MF, Williams BA, Merhige ME, Berman DS, Germano G, Beanlands RS, Min JK, Arasaratnam P, Sadreddini M, van Velthuijsen ML, Shaw LJ. Witbrodt B, et al. Among authors: kelkar aa. J Nucl Cardiol. 2017 Dec;24(6):1966-1975. doi: 10.1007/s12350-016-0569-1. Epub 2016 Sep 22. J Nucl Cardiol. 2017. PMID: 27659457
BACKGROUND: A drop in blood pressure (BP) or blunted BP response is an established high-risk marker during exercise myocardial perfusion imaging (MPI); however, data are sparse regarding the prognostic value of BP response in patients undergoing vasodilator stress rubidium …
BACKGROUND: A drop in blood pressure (BP) or blunted BP response is an established high-risk marker during exercise myocardial perfus …
Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012).
Vaduganathan M, Tahhan AS, Greene SJ, Kelkar AA, Georgiopoulou VV, Kalogeropoulos AP, Fonarow GC, Gheorghiade M, Butler J. Vaduganathan M, et al. Among authors: kelkar aa. Am J Cardiol. 2015 Jul 15;116(2):307-12. doi: 10.1016/j.amjcard.2015.03.062. Epub 2015 Apr 18. Am J Cardiol. 2015. PMID: 25963222 Clinical Trial.
We performed a systematic analysis of all cardiovascular device clinical trials from 2001 to 2012 published in medical and cardiovascular journals with the 8 highest impact factors. ...Each trial included a median of 335 patients (162 to 745) recruited from a
We performed a systematic analysis of all cardiovascular device clinical trials from 2001 to 2012 published in medical and cardiovasc …
Trends in characteristics of cardiovascular clinical trials 2001-2012.
Butler J, Tahhan AS, Georgiopoulou VV, Kelkar A, Lee M, Khan B, Peterson E, Fonarow GC, Kalogeropoulos AP, Gheorghiade M. Butler J, et al. Among authors: kelkar a. Am Heart J. 2015 Aug;170(2):263-72. doi: 10.1016/j.ahj.2015.05.006. Epub 2015 May 14. Am Heart J. 2015. PMID: 26299223 Review.
Trials enrolled a median of 452 patients (interquartile range 167-1,530) in 20 sites (2-76). Median duration was 2.1 (1.3-3.3) years, with an estimated enrollment rate of 1.1 (0.5-3.5) patients/site per month. ...
Trials enrolled a median of 452 patients (interquartile range 167-1,530) in 20 sites (2-76). Median duration was 2.1 (1.3-3.3) years, …
In-hospital worsening heart failure.
Butler J, Gheorghiade M, Kelkar A, Fonarow GC, Anker S, Greene SJ, Papadimitriou L, Collins S, Ruschitzka F, Yancy CW, Teerlink JR, Adams K, Cotter G, Ponikowski P, Felker GM, Metra M, Filippatos G. Butler J, et al. Among authors: kelkar a. Eur J Heart Fail. 2015 Nov;17(11):1104-13. doi: 10.1002/ejhf.333. Epub 2015 Aug 3. Eur J Heart Fail. 2015. PMID: 26235192 Review.
In this respect, WHF holds promise as a endpoint for acute heart failure clinical trials to better elucidate the benefit of targeted novel therapies. Better understanding of the pathophysiology and a consensus on the definition of WHF will further improve our epidem …
In this respect, WHF holds promise as a endpoint for acute heart failure clinical trials to better elucidate the benefit of targeted …
Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review.
Vaduganathan M, Samman-Tahhan A, Patel RB, Kelkar A, Papadimitriou L, Georgiopoulou VV, Greene SJ, Kalogeropoulos AP, Peterson E, Fonarow GC, Gheorghiade M, Butler J. Vaduganathan M, et al. Among authors: kelkar a. Int J Cardiol. 2017 Mar 1;230:301-303. doi: 10.1016/j.ijcard.2016.12.119. Epub 2016 Dec 22. Int J Cardiol. 2017. PMID: 28041703 Review. No abstract available.
10-Year Resource Utilization and Costs for Cardiovascular Care.
Shaw LJ, Goyal A, Mehta C, Xie J, Phillips L, Kelkar A, Knapper J, Berman DS, Nasir K, Veledar E, Blaha MJ, Blumenthal R, Min JK, Fazel R, Wilson PWF, Budoff MJ. Shaw LJ, et al. Among authors: kelkar a. J Am Coll Cardiol. 2018 Mar 13;71(10):1078-1089. doi: 10.1016/j.jacc.2017.12.064. J Am Coll Cardiol. 2018. PMID: 29519347 Free PMC article.
BACKGROUND: Cardiovascular disease (CVD) imparts a heavy economic burden on the U.S. health care system. Evidence regarding the long-term costs after comprehensive CVD screening is limited. ...Maintenance of a healthy population has the potential to markedly reduce …
BACKGROUND: Cardiovascular disease (CVD) imparts a heavy economic burden on the U.S. health care system. Evidence regarding the long- …
Team-Based Care for Managing Cardiac Comorbidities in Heart Failure.
Bellam N, Kelkar AA, Whellan DJ. Bellam N, et al. Among authors: kelkar aa. Heart Fail Clin. 2015 Jul;11(3):407-17. doi: 10.1016/j.hfc.2015.03.005. Heart Fail Clin. 2015. PMID: 26142638
J Card Fail 2002;8(4):222; with permission.) easier with the involvement of a team. Collaboration between physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care workers reduces the burden of care coordination and simultaneously im …
J Card Fail 2002;8(4):222; with permission.) easier with the involvement of a team. Collaboration between physicians, nurses, nurse p …
196 results
Jump to page
Feedback